Literature DB >> 25259741

Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels.

Roland E Schmieder1, Stephanie T Schmidt2, Thomas Riemer2, Ralf Dechend2, Ina Hagedorn2, Jochen Senges2, Franz H Messerli2, Uwe Zeymer2.   

Abstract

The long-term relationship between 24-hour ambulatory blood pressure (ABP) and office BP in patients on therapy is not well documented. From a registry we included all patients in whom antihypertensive therapy needed to be uptitrated. Drug treatment included the direct renin inhibitor aliskiren or an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or drugs not blocking the renin-angiotensin system, alone or on top of an existing drug regimen. In all patients, office BP and 24-hour ABP were obtained at baseline and after 1 year with validated devices. In the study population of 2722 patients, there was a good correlation between the change in office BP and 24-hour ABP (systolic: r=0.39; P<0.001; diastolic: r=0.34; P<0.001). However, the numeric decrease in office BP did not correspond to the decrease in ABP in a 1:1 fashion, for example, a decrease of 10, 20, and 30 mm Hg corresponded to a decrease of ≈7.2, 10.5, and 13.9 mm Hg in systolic ABP, respectively. The disproportionally greater decrease in systolic office BP compared with ABP was dependent on the level of the pretreatment BP, which was consistently higher for office BP than ABP. The white coat effect (difference between office BP and ABP) was on average 10/5 mm Hg lower 1 year after intensifying treatment and the magnitude of that was also dependent on pretreatment BP. There was a disproportionally greater decrease in systolic office BP than in ABP, which for both office BP and ABP seemed to depend on the pretreatment BP level.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  ambulatory blood pressure monitoring; blood pressure; hypertension

Mesh:

Substances:

Year:  2014        PMID: 25259741     DOI: 10.1161/HYPERTENSIONAHA.113.03140

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  Renal Denervation for Resistant Hypertension: Past, Present, and Future.

Authors:  Christian Ott; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 2.  Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials.

Authors:  Konstantinos Stavropoulos; Dimitrios Patoulias; Konstantinos Imprialos; Michael Doumas; Alexandra Katsimardou; Kyriakos Dimitriadis; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-12       Impact factor: 3.738

Review 3.  Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review.

Authors:  Noa Kallioinen; Andrew Hill; Mark S Horswill; Helen E Ward; Marcus O Watson
Journal:  J Hypertens       Date:  2017-03       Impact factor: 4.844

Review 4.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Authors:  Felix Mahfoud; Roland E Schmieder; Michel Azizi; Atul Pathak; Horst Sievert; Costas Tsioufis; Thomas Zeller; Stefan Bertog; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Sebastian Ewen; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Melvin D Lobo; Chaim Lotan; Thomas Felix Lüscher; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Faisal Sharif; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns
Journal:  Eur Heart J       Date:  2017-11-21       Impact factor: 29.983

Review 5.  New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension.

Authors:  Vasilios Papademetriou; Konstantinos Stavropoulos; Kostas Imprialos; Michael Doumas; Roland E Schmieder; Atul Pathak; Costas Tsioufis
Journal:  Int J Cardiol Hypertens       Date:  2019-11-09

6.  Antihypertensive drug effects according to the pretreatment self-measured home blood pressure: the HOMED-BP study.

Authors:  Hikari Sano; Azusa Hara; Kei Asayama; Seiko Miyazaki; Masahiro Kikuya; Yutaka Imai; Takayoshi Ohkubo
Journal:  BMJ Open       Date:  2020-12-12       Impact factor: 2.692

Review 7.  Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis.

Authors:  Mohan Palla; Hamidreza Saber; Sanjana Konda; Alexandros Briasoulis
Journal:  Integr Blood Press Control       Date:  2018-01-05

8.  Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.

Authors:  Rosario Pivonello; Irina Bancos; Richard A Feelders; Atil Y Kargi; Janice M Kerr; Murray B Gordon; Cary N Mariash; Massimo Terzolo; Noel Ellison; Andreas G Moraitis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-14       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.